Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marina Mojena is active.

Publication


Featured researches published by Marina Mojena.


Tetrahedron | 1992

The isolation and structure elucidation of zaragozic acid C, a novel potent squalene synthase inhibitor.

Claude Dufresne; Kenneth E. Wilson; Deborah L. Zink; Jack L. Smith; James D. Bergstrom; Marc M. Kurtz; Deborah J. Rew; Mary Nallin; Rosalind G. Jenkins; Ken Bartizal; Charlotte Trainor; Gerald F. Bills; Maria S. Meinz; Leeyuan Huang; Janet C. Onishi; James A. Milligan; Marina Mojena; Fernando Pelaez

Abstract The novel zaragozic acid C ( 1 ) has been isolated as a potent inhibitor of squalene synthase. It was found to be a competitive inhibitor of rat liver squalene synthase with an apparent K i of 45 ± 15 pM, and a broad spectrum antifungal agent against both yeast and filamentous fungi.


Molecular Diversity | 2005

Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3

John G. Ondeyka; Kithsiri Herath; Hiranthi Jayasuriya; Jon D. Polishook; Gerald F. Bills; Anne W. Dombrowski; Marina Mojena; Gregory E. Koch; Jerry DiSalvo; Julie A. DeMartino; Ziqiang Guan; Weerachai Nanakorn; Cori M. Morenberg; Michael J. Balick; Dennis W. Stevenson; Marc Slattery; Robert P. Borris; Sheo B. Singh

The chemokines (CXCL9, CXCL10 and CXCL11) and associated CXCR3 receptor are expressed during the inflammatory process from multiple sclerosis, atherosclerosis or organ transplantation resulting in the recruitment of lymphocytes leading to tissue damage. It is hypothesized that blocking of the ligand/CXCR3 receptor interaction has potential to provide opportunity for development of agents that would block tissue rejection. In this paper, four classes of natural product inhibitors (IC50 ranging 0.1–41 μM) have been described that block the CXCR3 receptor interaction of IP-10 ligand. These include a cyclic thiopeptide (duramycin), polyketide glycosides (roselipins), steroidal glycosides (hypoglausin A and dioscin) and a novel alkyl pyridinium alkaloid that were isolated by bioassay-guided fractionation of the organic extracts derived from actinomycete, fungal, plant and marine sources and discovered using 125 I IP-10/CXCR3 binding assay. Duramycin was the most potent with an IC50 of 0.1 μM. Roselipins 2A, 2B and 1A showed IC50 values of 14.6, 23.5, and 41 μM, respectively. Diosgenin glycosides dioscin, hypoglaucin A and kallstroemin D exhibited IC50 values of 2.1, 0.47 and 3 μM, respectively. A novel cyclic 3-alkyl pyridinium salt isolated from a sponge displayed a binding IC50 of 0.67 μ M.


Fungal Biology | 1994

Distribution of zaragozic acids (squalestatins) among filamentous ascomycetes

Gerald F. Bills; Fernando Pelaez; Jon D. Polishook; Maria Teresa Diez-Matas; Guy H. Harris; Wendy H. Clapp; Claude Dufresne; Kevin M. Byrne; Mary Nallin-Omstead; Rosalind G. Jenkins; Marina Mojena; Leeyuan Huang; James D. Bergstrom

The search for squalene synthase inhibitors of microbial origin has resulted in the discovery of a new class of fungal metabolites, the zaragozic acids (squalestatins). During our survey of representatives of most major groups of fungi and filamentous bacteria, the zaragozic acids were not found in prokaryotes Zygomycotina, or Basidiomycotina. All the fungal producers encountered to date are Ascomycotina, their related anamorphic states or sterile organisms with ascomycete affinities. Members of at least II different taxa of fungi are capable of making zaragozic acids. Zaragozic acid A (squalestatin 1) appears to be the most prevalent among the different fungal taxa. In several cases we have observed production in multiple strains of the same species; for example, nearly all strains of Sporormiella intermedia, that we have examined, produce zaragozic acid B. The discovery of the zaragozic acids illustrates how knowledge of fungal biology and biochemistry can enhance the search for new chemical entities. Simultaneous screening of fungi from diverse phylogenetic and ecological origins was emphasized to discover new zaragozic acids rather than simply relying on organisms from a single kind of substratum from geographically disparate sources.


Endocrinology | 2005

Direct Agonist/Antagonist Functions of Dehydroepiandrosterone

Fang Chen; Kristin Knecht; Elizabeth T. Birzin; John E. Fisher; Hilary A. Wilkinson; Marina Mojena; Consuelo Tudela Moreno; Azriel Schmidt; Shun-ichi Harada; Leonard P. Freedman; Alfred A. Reszka


Journal of Natural Products | 1993

Zaragozic Acids D and D2: Potent Inhibitors of Squalene Synthase and of Ras Farnesyl-Protein Transferase

Claude Dufresne; Kenneth E. Wilson; Sheo B. Singh; Deborah L. Zink; James D. Bergstrom; Deborah J. Rew; Jon D. Polishook; Maria S. Meinz; Leeyuan Huang; Keith C. Silverman; Russell B. Lingham; Marina Mojena; Carmen Cascales; Fernando Pelaez; Jackson B. Gibbs


Journal of Biological Chemistry | 2001

Peroxisome Proliferator-activated Receptor-γ-independent Inhibition of Macrophage Activation by the Non-thiazolidinedione Agonist L-796,449 COMPARISON WITH THE EFFECTS OF 15-DEOXY-Δ12,14-PROSTAGLANDIN J2

Antonio Castrillo; Marina Mojena; Sonsoles Hortelano; Lisardo Boscá


Bioorganic & Medicinal Chemistry Letters | 2006

Estrogen receptor β-subtype selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere

Robert R. Wilkening; Ronald W. Ratcliffe; A.K. Fried; Dongfang Meng; Wanying Sun; Lawrence F. Colwell; Sherrie Lambert; Mark L. Greenlee; Stefan Nilsson; Ann-Gerd Thorsell; Marina Mojena; Consuelo Tudela; Katalin Frisch; Wanda W.-S. Chan; Elizabeth T. Birzin; Susan P. Rohrer; Milton L. Hammond


Bioorganic & Medicinal Chemistry Letters | 2006

Androstenediol analogs as ER-β-selective SERMs

Timothy A. Blizzard; Candido Gude; Jerry D. Morgan; Wanda Chan; Elizabeth T. Birzin; Marina Mojena; Consuelo Tudela; Fang Chen; Kristin Knecht; Qin Su; Bryan Kraker; Ralph T. Mosley; Mark A. Holmes; Nandini Sharma; Paula M. D. Fitzgerald; Susan P. Rohrer; Milton L. Hammond


Archive | 1998

MEK inhibiting lactones

Gerald Bills; Maria Teresa Diez; Anne W. Dombrowski; Nicole D Falconi; Michael A. Goetz; David C. Heimbrook; Otto D. Hensens; Leeyuan Huang; Hans E. Huber; Rosalind G. Jenkins; Richard L. Kendall; Seok H. Lee; Marina Mojena; Allen Oliff; Denis R. Patrick; Fernando Pelaez; Jr Kenneth A Thomas; Dolores Vilella; Annie Z. Zhao; Deborah L. Zink


Botany | 1995

New fungal metabolites as potential antihypercholesterolemics and anticancer agents

Leeyuan Huang; Russell B. Lingham; Guy H. Harris; Sheo B. Singh; Claude Dufresne; Mary Nallin-Omstead; Gerald F. Bills; Marina Mojena; Manuel Sanchez; John D. Karkas; Jackson B. Gibbs; Wendy H. Clapp; Maria S. Meinz; Keith C. Silverman; James D. Bergstrom

Collaboration


Dive into the Marina Mojena's collaboration.

Top Co-Authors

Avatar

Gerald F. Bills

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fang Chen

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Kristin Knecht

United States Military Academy

View shared research outputs
Researchain Logo
Decentralizing Knowledge